Suggested Study as a Treatment Protocol for Coronavirus

Shahin, Mona

doi:10.21608/jsrs.2020.129935

Suggested Study as a Treatment Protocol for Coronavirus

Document Type : Original Article

Author

mona shahin

Zoology Department, Faculty of Women for Arts, Science and Education, Ain Shams University

10.21608/jsrs.2020.129935

Abstract

Coronaviruses are a large family of RNA viruses without segment, positive-sense RNA genomes and single-stranded, which cause illnesses. The disease ranging from mild in most people to diseases that is more dangerous. It may progress to pneumonia, acute respiratory distress syndrome and finally failure in vital function. Many people did not show symptoms of the disease. Clinical laboratory finding are low white cell counts with high rate of C-reactive protein. Chloroquine has positive antiviral effects on virus infection of primitive cells. In addition, these inhibitory effects were seen when the drug was used before and after exposure to the virus, this is important for both the preventive and curative architecture as well as therapeutic advantage of chloroquine. Meclizine and pyridoxine hydrochloride are considered strong anti-inflammatory, which help in controlling cytokine storm. Treatment by mixture of chloroquine, corticosterone, meclizine and pyridoxine may be protecting against blood clotting, which limits the spread of the disease. Accordingly, chloroquine, corticosterone, meclizine and pyridoxine can be used as prevention and treatment against pathogenic viral infections.

Keywords

References

[1] Caly, L.; Druce, J.D.; Catton, M.G.; Jans, D.A. & Wagstaff, K.M.,"The FDA- approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro", Antiviral Res. 104:(2020) 787-810

[2] Lim, Y.X.; Ng, Y.L.; Tam, J.P. & Liu, D.X. ,"Human Coronaviruses: A review of Virus-Host interactions", Diseases, 4: (2016) 120-128

[3] Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.& Lu, R.,"A Novel coronavirus from patients with pneumonia in china", N. Engl. J. Med., 12: ( 2019) 651–658

[4[ Drosten, C.; Gunther, S.; Preiser, W.; van der Werf, S.; Brodt, H.R.; Becker, S.; Rabenau, H.; Panning, M.; Kolesnikova, L. & Fouchier, R.A.,"Identification of a novel coronavirus in patients with severe acute respiratory syndrome", N. Engl. J. Med.,348: .( 2003)1967–1976.

[5] Zaki, A.M.; van Boheemen, S.; Bestebroer, T.M.; Osterhaus, A.D. & Fouchier, R.A., "Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia", N. Engl. J. Med., 367: (2012) 1814–1820

[6] Fehr, A.R. & Perlman, S. ,"An overview of their replication and pathogenesis" Methods Mol. Biol., 1282: (2015) 1–23.

[7] Bosch, B.J.; van der Zee, R.; de Haan, C.A. & Rottier, P.J.,"The coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex", J. Virol, 77: (2003) 8801–8811.

[8] Izaguirre,G.,"the Proteolytic Regulation of Virus Cell Entry by Furin and Other Proprotein Convertases",Viruses, 11: (2019) 837-855

[9] Bosch, B.J.; Bartelink, W. & Rottier, P.J. ,"Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide", J. Virol.,82: (2008) 8887–8890

[10] Nal, B.; Chan, C.; Kien, F.; Siu, L.; Tse, J.; Chu, K.; Kam, J.; Staropoli, I.; Crescenzo-Chaigne, B.& Escriou, N.,"Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E., J. Gen. Virol. 86: (2005) 1423–1434

[11] Siu, Y.L.; Teoh, K.T.; Lo, J.; Chan, C.M.; Kien, F.; Escriou, N.; Tsao, S.W.; Nicholls, J.M.; Altmeyer, R.& Peiris, J.S., "The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for assembly, tracking, and release of virus-like particles" J. Virol., 82: ( 2008) 11318–11330.

[12] Hurst, K.R.; Koetzner, C.A. & Masters, P.S. ,"Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein"J. Virol, 83: (2009) 7221–7234.

[13] Klausegger, A.; Strobl, B.; Regl, G.; Kaser, A.; Luytjes, W.& Vlasak, R. ,"Identification of a coronavirus hemagglutinin-esterase with a substrate specificity different from those of influenza C virus and bovine coronavirus"J. Virol.,73: (2009) 3737–3743.

[14] Savarino, A.; Boelaert ,J.R.; Cassone, A.; Majori, G.& Cauda, R.,"Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect "Dis.,3 : (2003) 722-733

[15] Muhammad, A .S. ; Suliman ,K. ; Abeer ,K. ;Nadia B. ; Rabeea,S.,"COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses "Journal of Advanced Research ,24: (2020) 91–98

[16] Shereen, M.A.; Suliman, K.; Abeer, K.; Nadia, B. Rabeea, S. ,"COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses" Journal of Advanced Research ,24: (2020) 91–98

[17] Liu, J.; Cao ,R.; Xu ,M.; Wang, X.; Zhang, H.; Hu ,H.," Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro" Cell Discov,6: (2020) 16-29

[18] Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J. & Xu, M.,"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"Cell Res., 30: (2020)269-277.

[19] White, .N.J.; Watson, J.A.; Hoglund, R.M.; Chan, X.H.; Cheah, P.Y. & Tarning, J.," COVID-19 prevention and treatment: a critical 707 analysis of chloroquin hydroxychloroquine clinical pharmacology"PLOS Medicine, (2020) in press.

[20] World Health Organization, (2015)

[21] Conan, N.J. ,"The treatment of hepatic amebiasis with chloroquine",The American journal of medicine, 623 : (1949)309–320.

[22] Borba , M.G.S. ; Val, F.F.A. ; Sampaio, V.S. ; Alexandre, M.A.A. ; Melo, G.C. ; Brito, M. ; Mourão, M.P.G. ; Brito-Sousa, J.D. ; Baía-da-Silva, D. ; Guerra, M.V.F. ; Hajjar, .LA. ; Pinto, R.C. ; Balieiro, A.A.S. ; Pacheco, A.G.F. ; Santos, J.D.O. ; Naveca, F.G. ,"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS595 CoV-2) infection: A randomized clinical trial",JAMA Network Open. 4: (2020)342–355

[23] Riou, B.;Barriot ,P.; Rimailho, A.& Baud, F.J.,"Treatment of severe chloroquine poisoning", N. Engl.J. Med., 318: (1988) 1–6.

[24] Mégarbane, B.; Bloch, V.; Hirt, D.; Debray,M.; Résiére, D.; Deye, N.& Baud, F.J.," Blood concentrations are better predictors of chioroquine poisoning severity than plasma concentrations: a prospective study with modeling of the concentration/effect relationships", Clin. Toxicol. 48: (2003) 904–915

[25] de Graaf, C.; Kooistra, A.J.; Vischer, H.F.;Katritch, V.; Kuijer, M.; Shiroishi, M.; Iwata, S.; Shimamura ,T.;Stevens, R.C.; de Esch, I.J.&Leurs, R. ,"Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor", J. Med.Chem., 54 : (2011) 8195–206

[26] Khilnani, G. & Khilnani, A.K. ,"Inverse agonism and its therapeutic significance",Ind. J. Pharmacol., 43 : (2011) 492–501

[27] Wiggins, S.A. & Griebling,T.,"Urinary Incontinence", Landon Center on Aging. Archived from the original on 2011, Retrieved ,14: (2011) 07-19

[28] van den Kommer, T. N.; Dik, M. G.; Comijs, H. C.; Jonker, C.& Deeg ,D. J. H.," Homocysteine and inflammation: predictors of cognitive decline in older persons. Neurobiology of Aging, J.neurobiolaging 31: ( 2010)1700–1709.

[29] Wu, J. T. ,"Circulating homocysteine is an inflammation marker and a risk factor of life-threatening inflammatory diseases "J. Biomed. Lab. Sci., 19: (2007)107–111

[30] Li, M.; Chen, J.; Li, Y.-S.; Feng ,Y.-B.; Gu, X.& Shi, C.Z. ,"Folic acid reduces adhesion molecules VCAM-1 expession in aortic of rats with hyperhomocysteinemia", International Journal of Cardiology,106: (2006)285–288

[31] Clarke, R., L.; Daly, K.; Robinson, E.; Naughten, S.; Cahalane, B.; & Graham, I. ,"Hyperhomocysteinemia: an independent risk factor for vascular disease", N. Engl. J. Med. 324: (1991) 1149–1155.

[32] Johan, B.; Ubbink, A.; Annatjie, V.; Rhena, D.; Robert, H.; & Vermaak,E.,"Vitamin B-6 and Homocysteine Metabolism",J. Clin. Invest., 98: (1996) 177–184

[33] Soedamah, M.S.S.; Chaturvedi, N.; Teerlink, T.; Idzior, W.R.; Fuller ,J.H.& Stehouwer, C.D.A.," Plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes: A cross-sectional nested case control study", J Intern Med., 258: (2005) 450–459

[34] Looker, H.C.; Fagot, C.A.; Gunter, E.W.; Pfeiffer, C.M.; Narayan ,K.M.V.& Knowler, W.C. ,"Homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes", Diabetologia, 46: (2003)766–772

[35] Yuecel, I.; Yeucel, G. & Mueftueoglu, F. ,"Plasma homocysteine levels in noninsulin-dependent diabetes mellitus with retinopathy and neovascular glaucoma",Int Ophthalmol.,25: (2004)201–205

[36] Yoshikaw, T. ,"Histamine N-Methyltransferase in the Brain",Int. J. Mol. Sci., 20: (2019) 737-758

[37] Ede, G. ,"Histamine Intolerance: why freshness matters",J. Evol. Health2 ,1: (2020) 23-39

[38] McEwen, B. S. & Wingfield, J. C. ,"the concept of allostasis in biology and biomedicine", Horm Behav 43: (2003) 2–15

[39] Remage-Healey, L. & Romero, L. M. ,"Daily and seasonal variation in response to stress in captive starlings Sturnus, glucose", Gen Comp Endocrinol. 119: (2000) 60–68.

[40] Hill, R.A.; Makin, H.L.J.; Kirk, D.N. & Murphy. G.M.,"Dictionary of Steroids",189: (1991) 978-990.

[41] Romeo, R. D., Tang, A. C., & Sullivan, R. M.,"Early life experiences: Enduring behavioral, neurological and endocrinological consequences. In D. W. Pfaff& A. M. Etgen (Eds.)",Molecular mechanisms of hormone actions on behavior.12: (2009)543-572.

[42] Eduardo, N.; Cozza, B.; Matkovic, C. ,"in Handbook of Hormones", (2016) : 529-530

[43] Priti, N.; & Emily M. ,"Meclizine: Safety and Efficacy in the Treatment and Prevention of Motion Sickness", Clinical Medicine Insights: Therapeutics,3: (2011) 179-183